From Company Creation through Public Investing
The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
